Basroparib

N/A

Report date: 2024/09/29 16:33:12
NME

Base Information

Drug NameBasroparib
Drug Alias NameSTP-1002STP06-1002STP1002
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTankyrase inhibitorsWnt signalling pathway inhibitors
TargetsTankyrase
Therapy Area/IndicationsSolid tumoursColorectal NeoplasmsCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSt Pharm Co LtdKorea Research Institute Of Chemical Technology
China Registration ClassN/A

Develop Information

Active CompaniesSt Pharm Co LtdGangneung Asan Hospital
Inactive CompaniesN/A
Active IndicationsSolid tumoursColorectal NeoplasmsCarcinoma, Renal Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A